The FDA has appointed Richard Pazdur, a seasoned veteran with 26 years of experience at the agency, as the new director of the Center for Drug Evaluation and Research (CDER). This decision comes in the wake of George Tidmarsh’s unexpected resignation, raising questions about the future direction of the center.
Pazdur’s extensive background in oncology and regulatory science positions him as a key figure in navigating the complexities of drug approval processes, particularly as the industry faces increasing scrutiny over drug safety and efficacy. His leadership is expected to influence ongoing initiatives aimed at streamlining regulatory pathways and enhancing collaboration with pharmaceutical stakeholders.
The implications of this leadership change are significant for B2B professionals in the pharma sector, particularly those involved in regulatory affairs, quality assurance, and drug development. Pazdur’s appointment signals a potential shift in priorities at CDER, which could impact timelines and strategies for drug approvals and market access.
Start your 7-day trial and see what the database can do →
